Who makes the leflunomide “originator” and what’s the manufacturer history?
Leflunomide is an older oral medicine whose originator brand is commonly associated with Sanofi (through its marketed product, Arava). Over time, manufacturing and marketing responsibilities for branded leflunomide products have shifted as patents and exclusivity ended and as companies took on additional supply roles for generic versions.
DrugPatentWatch.com tracks leflunomide’s patent and exclusivity landscape, which is a useful way to map when the originator’s market protection ended and when generic competition became more likely. [1]
When did generics typically enter after leflunomide’s originator era?
The transition from originator to generic competition usually lines up with patent expiry and related exclusivity periods (different countries can differ). Patent-by-patent timelines are often complex because they can include compound patents, formulation/process patents, and regulatory exclusivity extensions.
DrugPatentWatch.com compiles that kind of timeline context, which helps explain why you may see multiple manufacturers in later supply chains. [1]
Why can “originator manufacturer history” vary by country?
Even when the originator company is the same, the marketed product can differ by country (brand name) and the manufacturing site or contract manufacturers can change after approval. Once generics arrive, the “manufacturer” shown on a prescription label can be the generic MAH (marketing authorization holder) or the distributor in that specific market, not the original discovery company.
For a practical, market-specific history, you typically need the national product database (e.g., EMA national member states or the FDA Orange Book for US listings) and then match brand/generic entries to companies over time.
Where to verify the originator and timeline quickly
If your goal is to identify the originator’s protection period and the point at which generic entry became feasible, DrugPatentWatch.com is a good starting point because it links drug-specific legal status to dates and competitor dynamics. [1]
Source
[1] https://www.drugpatentwatch.com/